Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00058045 · ClinicalTrials.gov registry record · Phase 1
Interleukin-2 and Stem Cell Factor in Treating Patients With AIDS or AIDS-Related Cancer
A Phase 1 study, sponsored by Roswell Park Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT00058045: Completed Phase 1 study, sponsored by Roswell Park Cancer Institute.
NCT00058045 is a Phase 1 study that has completed, run by Roswell Park Cancer Institute. The registered enrollment target is 1 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00058045, a Phase 1 study, has completed, sponsored by Roswell Park Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill cancer cells. Stem cell factor may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of cancer therapy. PURPOSE: Phase I trial to study the effectiveness of combining interleukin-2 with stem cell factor in treating patients who have AIDS or AIDS-related cancer.
Interventions
- BIOLOGICAL aldesleukin
- BIOLOGICAL recombinant human stem cell factor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2002-08 |
| Phase | Phase 1 |
What the finished NCT00058045 record still lists
NCT00058045 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which aldesleukin is the first listed.
NCT00058045 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00058045 about?
NCT00058045 is a clinical study titled "Interleukin-2 and Stem Cell Factor in Treating Patients With AIDS or AIDS-Related Cancer". RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill cancer cells. Stem cell factor may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of cancer therapy. PURPOSE: Phase I trial t...
What is the current status of trial NCT00058045?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2002-08.
What interventions are being tested in trial NCT00058045?
The interventions under investigation include: aldesleukin (BIOLOGICAL), recombinant human stem cell factor (BIOLOGICAL).
Who is sponsoring clinical trial NCT00058045?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00058045's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia